Claiborne Cary J, CEO of Adial Pharmaceuticals, reported no transactions involving non-derivative securities as of 12/05/2024. The announcement indicates that there were no changes in his stock holdings during this period.This report is significant for investors monitoring insider activities, as it confirms the absence of stock sales or purchases by the CEO. Such information can be crucial for assessing insider confidence in the company's future performance.Investors should note that the lack of transactions does not imply any specific outlook on the company's stock performance. It merely reflects the current status of the CEO's holdings as of the reported date.

Claiborne Cary J, CEO of Adial Pharmaceuticals, reported no transactions involving non-derivative securities as of 12/05/2024. The announcement indicates that there were no changes in his stock holdings during this period.This report is significant for investors monitoring insider activities, as it confirms the absence of stock sales or purchases by the CEO. Such information can be crucial for assessing insider confidence in the company's future performance.Investors should note that the lack of transactions does not imply any specific outlook on the company's stock performance. It merely reflects the current status of the CEO's holdings as of the reported date.